MGNX analyst estimates
MacroGenics (MGNX) analyst ratings, the average price target and its range, and every firm's latest call.
- 2 firms rate MGNX: 2 buy, 0 hold, 0 sell.
- The average price target is $6.00 from None analysts, from $6.00 to $6.00.
MGNX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Apr 20, 2026 | Barclays | MacroGenics price target raised to $6 from $4 at Barclays | $6.00 |
| May 14, 2025 | Barclays | MacroGenics price target lowered to $3 from $8 at Barclays | $3.00 |
| Mar 25, 2025 | H.C. Wainwright | MacroGenics price target lowered to $2 from $4 at H.C. Wainwright | $2.00 |
| Aug 7, 2024 | Stifel Nicolaus | MacroGenics (MGNX) PT Lowered to $6 at Stifel | $6.00 |
| Jul 31, 2024 | B.Riley Financial | B.Riley Downgrades MacroGenics (MGNX) to Neutral | $5.00 |
| Jul 31, 2024 | JMP Securities | MacroGenics price target lowered to $8 from $16 at JMP Securities | $8.00 |
| Jul 29, 2024 | Barclays | MacroGenics price target lowered to $9 from $14 at Barclays | $9.00 |
| May 23, 2024 | BTIG | MacroGenics price target lowered to $9 from $24 at BTIG | $9.00 |
| May 13, 2024 | H.C. Wainwright | MacroGenics (MGNX) PT Lowered to $4 at H.C. Wainwright | $4.00 |
| May 10, 2024 | BMO Capital | MacroGenics downgraded to Market Perform from Outperform at BMO Capital | $8.00 |
| May 10, 2024 | Barclays | MacroGenics price target lowered to $14 from $25 at Barclays | $14.00 |
| Apr 4, 2024 | Stifel Nicolaus | Stifel on MacroGenics (MGNX): 'incrementally more positive', 'We remain buyers into the next “by May 31” clinical update' | $29.00 |
| Nov 22, 2022 | Guggenheim | Guggenheim Upgrades MacroGenics (MGNX) to Buy | $12.00 |
| Jul 11, 2022 | BTIG | MacroGenics price target lowered to $6 at BTIG | $6.00 |
| Jun 16, 2021 | Wedbush | MacroGenics (MGNX) PT Lowered to $32 at Wedbush, Following Clinical Business Update | $32.00 |